Fulgent Genetics, Inc.

FLGT Healthcare Diagnostics & Research

Fulgent Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $322.7 million, up 13.8% from fiscal 2024. In the quarter to June 2026, revenue grew 4.38%, EPS fell 69.4% and free cash flow grew 25.4%, each against the same quarter a year earlier.

19.81 1.53 −7.17%
Market cap
$587.2M
P/E
0.0×
Fwd P/E
−5.8×
Dividend yield
—
F-score
4/9
Altman Z
5.63
Beneish M
−2.35
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
5 2 4 7

+8 more TTM periods

ROE
(8.01%) (6.81%) (5.41%) (3.81%)
ROA
(7.37%) (6.25%) (4.97%) (3.51%)
ROIC
(10.34%) (8.62%) (7.39%) (5.96%)
Return on Tangible Assets
(17.01%) (14.61%) (10.47%) (7.86%)
Average Days of Receivables
73.17 78.93 95.88 82.34
Free Cash Flow per Share
(3.71) (3.66) (4.04) (0.65)
Free Cash Flow
(103.78) (113.16) (124.21) (19.84)
Capital Expenditures
(20.08) (23.05) (22.57) (21.37)
Other line items
Cash ROIC
(8.28%) (8.57%) (8.61%) (1.33%)
Accounts Receivable Turnover
4.56 4.55 4.20 4.91
Accounts Payable Turnover
12.12 9.98 10.36 9.79
Inventory Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
27.21 39.27 35.50 35.61
Days of Inventory on Hand
0.00 0.00 0.00 0.00
Tax Rate
(0.08) (0.11) (0.12) (0.09)
Research and Development Expense of Revenue
17.52% 17.38% 16.71% 16.43%
Selling, General and Administrative Expense of Revenue
52.46% 51.88% 49.60% 44.78%
Share Based Compensation of Revenue
11.58% 12.15% 12.27% 12.90%
Interest Coverage
(1,019.02) (1,357.99) (1,214.61) (717.10)
Operating CF/Net income
0.99 1.22 1.68 (0.04)
Depreciation/Fixed assets
0.20 0.17 0.17 0.16
Capex/Depreciation
(0.91) (1.16) (1.19) (1.16)
Revenue per Share
11.57 10.37 10.48 10.26
Operating CF per Share
(2.99) (2.92) (3.30) 0.05
Capex per Share
(0.72) (0.75) (0.73) (0.69)
Capex to Sales
0.06 0.07 0.07 0.07

Fold the line items

Columns are period end dates